Company Overview and News
BISHOPSGATE, LONDON / ACCESSWIRE / December 5, 2017 / In accordance with the Disclosure and Transparency Rules ("DTR"), SolGold Plc (the "Company") was informed by DGR Global Ltd that, in fulfilment of the obligations of Rule 5 of the DTR, it continues to hold 204,151,800 ordinary shares. However, after taking into account the shares allotted and admitted to trading for the recent capital placings including the most recent "bought deal" private placement of 180,000,000 ordinary shares in the Company completed on 30 November 2017, its interest has decreased from 13.
LONDON, UK / ACCESSWIRE / October 31, 2017 / The Board of SolGold (TIDM: SOLG) is pleased to provide an update on its 100% owned Machos - Florida Santa Cruz- La Hueca Project ("the Project") in Southern Ecuador.
LONDON, UK / ACCESSWIRE / October 6, 2017 / Following the publication of its prospectus on 2 October 2017, SolGold Plc is pleased to announce the admission of its entire issued share capital to the Official List of the UKLA by way of a standard listing under Chapter 14 of the UKLA's Listing Rules and to trading on the London Stock Exchange's main market for listed securities (the 'Admission'). Dealings will commence at 08.
LONDON, UK / ACCESSWIRE / October 3, 2017 / Further to the announcement of 18 August 2017, the Board of SolGold (the "Board") (LSE: SOLG; TSX: SOLG) is pleased to announce that the Company has issued a prospectus in connection with its admission to listing of its ordinary shares (the "Ordinary Shares") on the Standard Listing segment of the Official List of the UK Listing Authority (the "Official List") and admission to trading on the main market for listed securities (the "Main Market") of London Stock Exchange plc (the "London Stock Exchange") (together, "Admission").
LONDON, UK / ACCESSWIRE / September 14, 2017 / The Board of SolGold (LSE: SOLG; TSX: SOLG) is pleased to provide all shareholders and interested investors with access to additional information required to be filed in Canada in connection with the Company's financial year ended 30 June 2017.
Further to the announcement of 21 July 2017, the Board of SolGold (the "Board") today announces that admission to listing of its ordinary shares (the "Ordinary Shares") on the Standard Listing segment of the Official List of the UK Listing Authority (the "Official List") and admission to trading on the main market for listed securities (the "Main Market") of London Stock Exchange plc (the "London Stock Exchange") (together, "Admission") has been delayed.
In accordance with the Disclosure and Transparency Rules ("DTR"), SolGold Plc (the "Company") was informed by Cornerstone Capital Resources Inc ("Cornerstone") on 17 August 2017 that, in fulfilment of the obligations of Rule 5 of the DTR, and as a result of the purchase of shares with voting rights made on 16 August 2017, Cornerstone has completed the acquisition of the further 15,750,000 ordinary shares of 1 penny each in the Company as previously announced in the update of its holdings on 14 July 2017.
The Board of SolGold plc ("SolGold" or the "Company") wishes to advise of the issue and allotment of 690,000 fully paid ordinary share of 1p each in the capital of the Company to Newcrest International Pty Ltd, a wholly owned subsidiary of ASX-listed Newcrest Mining Ltd ("Newcrest"), Australia's largest gold miner and lock cave mining expert.
IronRidge Resources Limited (AIM: IRR, 'IronRidge' or the 'Company') is pleased to announce that infill soil sampling results have been received and that significant gold in soil anomalies are confirmed, further enhancing the prospectivity of the Bodite Project in Ivory Coast, West Africa.
IronRidge Resources Limited (AIM: IRR, 'IronRidge' or the 'Company') is pleased to announce that ongoing trenching and mapping at the Barari license, Ewoyaa and Abunko Projects, continues to intersect wide spodumene dominant lithium pegmatites within the Cape Coast Lithium Project area, Ghana, West Africa. The Company is working towards a maiden drill programme later this year.
2h - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...